Compare Charles Schwab Corporation Common Stock (SCHW) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs GeneDx Holdings Corp — how do they compare? Charles Schwab Corporation Common Stock trades at $97.01 (market cap $167.52B), while GeneDx Holdings Corp trades at $67.75 (market cap $2.02B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 82.9× GeneDx Holdings Corp's market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles Schwab Corporation Common Stock for 85 Days and GeneDx Holdings Corp for 19 Days on average.
| SCHW | WGS | |
|---|---|---|
Market Cap | $167.52B | $2.02B |
Volume | 6,554,126 | 734,640 |
Sector | Financials | Health |
52-Week High | $113.65 | $167.51 |
52-Week Low | $85.35 | $34.51 |
Typical Hold Time | 85 Days | 19 Days |
Enterprise Value | $153.97B | $2.05B |
Dividend Yield | 1.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $96.80, up 1.28% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 17.64, net income margin of 38.79%, and robust cash flow. Recent news highlights growth in client assets to $13.41 trillion and a strategic AI partnership with Anthropic.
The outlook is positive with a consensus price target of $120.33, implying significant upside. Risks include competitive pressures and market volatility, but strong earnings momentum and a favorable industry growth forecast support a bullish case for long-term investors.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
